OVER DEZE AFLEVERING
Osivax and GC Biopharma team up on a next-generation flu vaccine, K2 Therapeutics' Ying Huang talks through why so few drugs make it to market, and the Trump administration opens a new round of Medicaid drug pricing deals.
Engels
Verenigde Staten
TRANSCRIPTIE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
OUDE AFLEVERINGEN ZOEKEN
Zoek naar eerdere afleveringen van Pharmaceutical Executive.
ANDERE AFLEVERINGEN IN DEZE PODCAST
Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.
Can artificial intelligence help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In this episode of the Pharm Exec podcast, Matt Walz, CEO of Trialbee, a patient recruitment company, joins Mike Christel, group …
Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.
Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicine.
Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.
Disclaimer: De podcast en de illustraties die op deze pagina zijn ingesloten, zijn afkomstig van Pharmaceutical Executive Podcast, eigendom van de eigenaar en niet gelieerd aan of goedgekeurd door Listen Notes, Inc.
BEWERKEN
Bedankt voor uw hulp bij het up-to-date te houden van de podcast-database .
